Inhibition of TWIST1 leads to activation of oncogene-induced senescence in oncogene-driven non-small cell lung cancer

• Published in: Molecular cancer research Vol. 11; no. 4; pp. 329 - 338
• Main Authors: Burns, Timothy F, Dobromilskaya, Irina, Murphy, Sara C, Gajula, Rajendra P, Thiyagarajan, Saravanan, Chatley, Sarah N H, Aziz, Khaled, Cho, Yoon-Jae, Tran, Phuoc T, Rudin, Charles M
• Format: Journal Article
• Language: English
• Published: United States 01.04.2013
• Subjects: Animals; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - pathology; Cell Line, Tumor; Cellular Senescence - genetics; Gene Silencing; HEK293 Cells; Heterografts; Humans; Lung Neoplasms - genetics; Lung Neoplasms - pathology; Mice; Mice, Inbred NOD; Mice, SCID; Nuclear Proteins - antagonists & inhibitors; Nuclear Proteins - genetics; Nuclear Proteins - metabolism; Oncogenes; RNA, Small Interfering - administration & dosage; RNA, Small Interfering - genetics; Twist-Related Protein 1 - antagonists & inhibitors; Twist-Related Protein 1 - genetics; Twist-Related Protein 1 - metabolism
• ISSN: 1541-7786; 1557-3125
• DOI: 10.1158/1541-7786.MCR-12-0456

A large fraction of non-small cell lung cancers (NSCLC) are dependent on defined oncogenic driver mutations. Although targeted agents exist for EGFR- and EML4-ALK-driven NSCLCs, no therapies target the most frequently found driver mutation, KRAS. Furthermore, acquired resistance to the currently targetable driver mutations is nearly universally observed. Clearly a novel therapeutic approach is needed to target oncogene-driven NSCLCs. We recently showed that the basic helix-loop-helix transcription factor Twist1 cooperates with mutant Kras to induce lung adenocarcinoma in transgenic mouse models and that inhibition of Twist1 in these models led to Kras-induced senescence. In the current study, we examine the role of TWIST1 in oncogene-driven human NSCLCs. Silencing of TWIST1 in KRAS-mutant human NSCLC cell lines resulted in dramatic growth inhibition and either activation of a latent oncogene-induced senescence program or, in some cases, apoptosis. Similar effects were observed in EGFR mutation-driven and c-Met-amplified NSCLC cell lines. Growth inhibition by silencing of TWIST1 was independent of p53 or p16 mutational status and did not require previously defined mediators of senescence, p21 and p27, nor could this phenotype be rescued by overexpression of SKP2. In xenograft models, silencing of TWIST1 resulted in significant growth inhibition of KRAS-mutant, EGFR-mutant, and c-Met-amplified NSCLCs. Remarkably, inducible silencing of TWIST1 resulted in significant growth inhibition of established KRAS-mutant tumors. Together these findings suggest that silencing of TWIST1 in oncogene driver-dependent NSCLCs represents a novel and promising therapeutic strategy.